Stock Earnings

Question 1

¿Cuáles son los estados financieros clave de Northwest Biotherapeutics Inc?

Accepted Answer

Según el último estado financiero (Form-10K), Northwest Biotherapeutics Inc tiene un total de activos de $26, una ganancia neta loss de $-85

Question 2

¿Cuáles son los ratios financieros clave para NWBO?

Accepted Answer

El ratio corriente de Northwest Biotherapeutics Inc es 0.24, el margen neto es -8,500, las ventas por acción son $0.

Question 3

¿Cómo se desglosan los ingresos de Northwest Biotherapeutics Inc por segmento o geografía?

Accepted Answer

Northwest Biotherapeutics Inc largest revenue segment is Innovative Immunotherapies for Cancer, at a revenue of 1,932,000 in the most earnings release.For geography, United States, Germany, United Kingdom and Netherlands is the primary market for Northwest Biotherapeutics Inc, at a revenue of 1,932,000.

Question 4

¿Es rentable Northwest Biotherapeutics Inc?

Accepted Answer

no, según los últimos estados financieros, Northwest Biotherapeutics Inc tiene una ganancia neta loss de $-85

Question 5

¿Tiene Northwest Biotherapeutics Inc alguna deuda?

Accepted Answer

yes, Northwest Biotherapeutics Inc tiene una deuda de 105

Question 6

¿Cuántas acciones en circulación tiene Northwest Biotherapeutics Inc?

Accepted Answer

Northwest Biotherapeutics Inc tiene un total de acciones en circulación de 1,328.6

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	1	1	1	1	1	1
Revenue Growth (YoY)	0%	0%	0%	0%	0%	-50%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	32	33	29	33	33	54
Research & Development	34	34	27	35	20	33
Operating Expenses	66	67	57	68	53	87
Other Non Operating Income (Expenses)	9	6	-2	--	0	--
Pretax Income	-82	-83	-62	-105	179	-529
Income Tax Expense	--	0	0	0	--	--
Net Income	-83	-85	-64	-105	179	-529
Net Income Growth	11%	33%	-39%	-159%	-134%	2,545%
Shares Outstanding (Diluted)	1,438.19	1,242.23	1,119.19	1,015.85	873.52	725.13
Shares Change (YoY)	18%	11%	10%	16%	20%	28.99%
EPS (Diluted)	-0.06	-0.06	-0.05	-0.1	0.21	-0.73
EPS Growth	-7%	19%	-43%	-148%	-129%	1,725%
Free Cash Flow	-45	-58	-57	-55	-44	-38
Free Cash Flow Per Share	-0.03	-0.04	-0.05	-0.05	-0.05	-0.05
Gross Margin	--	--	--	--	--	--
Operating Margin	-6,500%	-6,600%	-5,500%	-6,700%	-5,200%	-8,600%
Profit Margin	-8,300%	-8,500%	-6,400%	-10,500%	17,900%	-52,900%
Free Cash Flow Margin	-4,500%	-5,800%	-5,700%	-5,500%	-4,400%	-3,800%
EBITDA	-64	-65	-54	-66	-52	-86
EBITDA Margin	-6,400%	-6,500%	-5,400%	-6,600%	-5,200%	-8,600%
D&A For EBITDA	1	1	1	1	0	0
EBIT	-65	-66	-55	-67	-52	-86
EBIT Margin	-6,500%	-6,600%	-5,500%	-6,700%	-5,200%	-8,600%
Effective Tax Rate	--	0%	0%	0%	--	--

Northwest Biotherapeutics Inc (NWBO) Price

NWBO Stock Price Chart

NWBO Income

Follow-Up Questions